Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
SSE:688621.SS
54.23 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||
| Current Assets: | ||||||||
| Cash & Cash Equivalents
| 565.564 | 690.931 | 608.93 | 490.251 | 109.305 | 76.489 | 31.702 | 5.62 |
| Short Term Investments
| 30 | 30 | 13.107 | 157.6 | 5.09 | 0 | 0.07 | 0 |
| Cash and Short Term Investments
| 595.564 | 720.931 | 622.037 | 647.851 | 109.305 | 76.489 | 31.702 | 5.62 |
| Net Receivables
| 785.117 | 555.831 | 362.734 | 258.249 | 112.778 | 75.437 | 56.169 | 55.795 |
| Inventory
| 15.046 | 14.409 | 12.537 | 7.84 | 6.289 | 3.741 | 3.893 | 1.491 |
| Other Current Assets
| 118.765 | 65.967 | 42.655 | 27.845 | 34.503 | 25.864 | 39.526 | 58.666 |
| Total Current Assets
| 1,514.492 | 1,357.138 | 1,039.963 | 941.785 | 262.875 | 181.531 | 119.073 | 65.776 |
| Non-Current Assets: | ||||||||
| Property, Plant & Equipment, Net
| 211.611 | 220.264 | 197.017 | 161.052 | 74.64 | 63.093 | 50.9 | 36.493 |
| Goodwill
| 26.057 | 26.057 | 26.057 | 26.057 | 26.057 | 20.511 | 20.511 | 0 |
| Intangible Assets
| 5.411 | 5.387 | 4.199 | 3.324 | 4.041 | 4.056 | 1.694 | 1.718 |
| Goodwill and Intangible Assets
| 31.468 | 31.444 | 30.256 | 29.381 | 30.098 | 24.567 | 22.205 | 1.718 |
| Long Term Investments
| 75.802 | 100.75 | 81.643 | -117.6 | 13.158 | 12.867 | 3.964 | 1.822 |
| Tax Assets
| 64.039 | 38.929 | 16.081 | 5.034 | 2.655 | 1.972 | 2.328 | 1.177 |
| Other Non-Current Assets
| 89.892 | 114.494 | 98.134 | 222.998 | 1.429 | 1.485 | 3.028 | 3.086 |
| Total Non-Current Assets
| 472.811 | 505.88 | 423.131 | 300.866 | 121.98 | 103.984 | 82.425 | 44.297 |
| Total Assets
| 1,987.304 | 1,863.018 | 1,463.094 | 1,242.651 | 384.855 | 285.515 | 201.498 | 110.073 |
| Liabilities & Equity: | ||||||||
| Current Liabilities: | ||||||||
| Account Payables
| 37.696 | 56.766 | 33.031 | 18.355 | 13.628 | 15.844 | 8.794 | 1.355 |
| Short Term Debt
| 309.391 | 383.929 | 201.172 | 138.005 | -120.931 | 15.862 | 4.875 | 24.58 |
| Tax Payables
| 17.022 | 30.513 | 20.874 | 17.471 | 7.122 | 4.803 | 3.969 | 1.564 |
| Deferred Revenue
| 0 | 0 | 205.855 | 238.142 | 152.571 | 22.493 | 3.969 | 15.642 |
| Other Current Liabilities
| 414.455 | 289.998 | 263.116 | 44.143 | 29.217 | 107.757 | 106.176 | 40.586 |
| Total Current Liabilities
| 778.564 | 761.205 | 518.192 | 417.826 | 191.937 | 166.759 | 123.814 | 68.085 |
| Non-Current Liabilities: | ||||||||
| Long Term Debt
| 102.322 | 40.623 | 33.845 | 49.723 | 31.017 | 0 | 0 | 0 |
| Deferred Revenue Non-Current
| 2.52 | 3.585 | 2.825 | 5.46 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 1.246 | 0.347 | -2.825 | -5.46 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 0 | 0 | 0.243 | 0 | 0 | 0 | 3.862 | 8.737 |
| Total Non-Current Liabilities
| 106.088 | 44.554 | 36.67 | 55.183 | 31.017 | 0 | 3.862 | 8.737 |
| Total Liabilities
| 884.652 | 805.76 | 554.862 | 473.009 | 191.937 | 166.759 | 127.675 | 76.822 |
| Equity: | ||||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock
| 112 | 112 | 80 | 80 | 60 | 16.304 | 16.304 | 15 |
| Retained Earnings
| 563.362 | 415.889 | 293.502 | 171.298 | 73.107 | 72.182 | 27.947 | 8.842 |
| Accumulated Other Comprehensive Income/Loss
| 0 | 0 | 23.35 | 10.805 | 6.666 | 28.153 | 30.988 | 0 |
| Other Total Stockholders Equity
| 425.275 | 512.123 | 523.173 | 510.651 | 49.331 | 28.153 | 30.988 | 10.269 |
| Total Shareholders Equity
| 1,100.637 | 1,040.012 | 896.698 | 761.949 | 189.105 | 116.64 | 75.239 | 34.111 |
| Total Equity
| 1,102.652 | 1,057.259 | 908.232 | 769.642 | 192.918 | 118.756 | 73.823 | 33.252 |
| Total Liabilities & Shareholders Equity
| 1,987.304 | 1,863.018 | 1,463.094 | 1,242.651 | 384.855 | 285.515 | 201.498 | 110.073 |